We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Prototype Vaccine Protects Against Multiple Chlamydia Strains

By LabMedica International staff writers
Posted on 03 Aug 2016
A prototype vaccine to protect against Chlamydia trachomatis infection gave promising results when tested in vitro and in a mouse model system.

C. More...
trachomatis infections in women are often asymptomatic and, if left untreated, can lead to significant complications including pelvic inflammatory disease and tubal factor infertility. Vaccine development efforts over the past 30 years have been unproductive, and currently there is no vaccine approved for use in humans.

There are several serologically distinct strains or serovars of C. trachomatis, which means that any potential vaccine would need to provide protection against multiple serovars. To accomplish this task, investigators at McMaster University (Hamilton, ON, Canada) based their vaccine on the components of a highly conserved type III secretion system (T3SS) composed of both structural and effector proteins, which is an essential virulence factor for infection and intracellular replication.

In the current study they evaluated a novel fusion protein antigen (BD584), which consisted of three T3SS proteins from C. trachomatis (CopB, CopD, and CT584) as a potential chlamydial vaccine candidate.

The investigators reported in the June 17, 2016, online edition of the journal Vaccine that intranasal immunization with BD584 elicited serum-neutralizing antibodies that inhibited C. trachomatis infection in vitro. Following intravaginal challenge with C. muridarum, immunized mice had a 95% reduction in chlamydial shedding from the vagina at the peak of infection and cleared the infection sooner than control mice. Immunization with BD584 also reduced the rate of hydrosalpinx (distally blocked fallopian tubes filled with serous or clear fluid) by 87.5% compared to control mice.

These results suggested that highly conserved proteins of the chlamydial T3SS may represent good candidates for a Chlamydia vaccine.

“Vaccine development efforts in the past three decades have been unproductive and there is no vaccine approved for use in humans,” said first author Dr. David Bulir, a researcher at McMaster University. “Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.”

Related Links:
McMaster University



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.